ATRA's logo.
Ticker Symbol: ATRA

Atara Biotherapeutics Inc

$17.37 - 02-10-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001604464

Company Profile

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 611 Gateway Blvd Ste 900
CEO: Pascal Touchon
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $1.37
Change: -$0.01 ( -0.73%)
Days Range: $1.28 - $1.43
Beta: 2.53
52wk. High: $5.64
52wk. Low: $1.25
Ytd. Change -58.96%
50 Day Moving Average: $1.55
200 Day Moving Average: $1.95
Shares Outstanding: 101102152

Valuation

Market Cap: 13.9B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A